Phase I/II Study of a Five-fraction Hypofractionated Accelerated Radiotherapy Treatment for Low-risk Localised Prostate Cancer: Early Results of pHART3

Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2007. Toronto, 2007.

Lukka, 2001, Controversies in prostate cancer radiotherapy: consensus development, Can J Urol, 8, 1314

D'Amico, 1999, Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer, J Clin Oncol, 17, 168, 10.1200/JCO.1999.17.1.168

D'Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, Jama, 280, 969, 10.1001/jama.280.11.969

Cooperberg, 2007, Contemporary trends in low risk prostate cancer: risk assessment and treatment, J Urol, 178, S14, 10.1016/j.juro.2007.03.135

Zelefsky, 2007, Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 67, 65, 10.1016/j.ijrobp.2006.08.030

Thames, 1982, Changes in early and late radiation responses with altered dose fractionation: implications for dose–survival relationships, Int J Radiat Oncol Biol Phys, 8, 219, 10.1016/0360-3016(82)90517-X

Hall, 2005

Hoskin, 2007, Hypofractionation in clinical trials for prostate cancer, Clin Oncol (R Coll Radiol), 19, 287, 10.1016/j.clon.2007.03.007

Dasu, 2007, Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?, Clin Oncol (R Coll Radiol), 19, 289, 10.1016/j.clon.2007.02.007

Williams, 2007, Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer, Int J Radiat Oncol Biol Phys, 68, 24, 10.1016/j.ijrobp.2006.12.036

Loblaw, 2006, External beam irradiation for localized prostate cancer—the promise of hypofractionation, Can J Urol, 13, 62

Bentzen, 2005, The alpha/beta ratio for prostate cancer: what is it, really?, Radiother Oncol, 76, 1, 10.1016/j.radonc.2005.06.009

Fowler, 2003, What hypofractionated protocols should be tested for prostate cancer?, Int J Radiat Oncol Biol Phys, 56, 1093, 10.1016/S0360-3016(03)00132-9

Brenner, 2002, Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue, Int J Radiat Oncol Biol Phys, 52, 6, 10.1016/S0360-3016(01)02664-5

Pollack, 2002, Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial, Int J Radiat Oncol Biol Phys, 53, 1097, 10.1016/S0360-3016(02)02829-8

Zietman, 2005, Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial, Jama, 294, 1233, 10.1001/jama.294.10.1233

Peeters, 2006, Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy, J Clin Oncol, 24, 1990, 10.1200/JCO.2005.05.2530

Dearnaley, 2007, Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial, Lancet Oncol, 8, 475, 10.1016/S1470-2045(07)70143-2

Fowler, 2005, The radiobiology of prostate cancer including new aspects of fractionated radiotherapy, Acta Oncol, 44, 265, 10.1080/02841860410002824

Brenner, 1999, Fractionation and protraction for radiotherapy of prostate carcinoma, Int J Radiat Oncol Biol Phys, 43, 1095, 10.1016/S0360-3016(98)00438-6

Madsen, 2007, Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results, Int J Radiat Oncol Biol Phys, 67, 1099, 10.1016/j.ijrobp.2006.10.050

Crook, 1995, Prostate motion during standard radiotherapy as assessed by fiducial markers, Radiother Oncol, 37, 35, 10.1016/0167-8140(95)01613-L

Ten Haken, 1991, Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder, Int J Radiat Oncol Biol Phys, 20, 1317, 10.1016/0360-3016(91)90244-X

Cheung, 2005, Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer, Int J Radiat Oncol Biol Phys, 62, 418, 10.1016/j.ijrobp.2004.09.051

Beltran, 2008, Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods, Int J Radiat Oncol Biol Phys, 70, 289, 10.1016/j.ijrobp.2007.08.040

Greene, 2002

Barry, 1992, The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association, J Urol, 148, 1549, 10.1016/S0022-5347(17)36966-5

Boersma, 1998, Estimation of the incidence of late bladder and rectum complications after high-dose (70–78Gy) conformal radiotherapy for prostate cancer, using dose–volume histograms, Int J Radiat Oncol Biol Phys, 41, 83, 10.1016/S0360-3016(98)00037-6

Fiorino, 2002, Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions, Radiother Oncol, 64, 1, 10.1016/S0167-8140(02)00147-0

Greco, 2003, Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer, Radiother Oncol, 69, 215, 10.1016/j.radonc.2003.08.003

Storey, 2000, Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial, Int J Radiat Oncol Biol Phys, 48, 635, 10.1016/S0360-3016(00)00700-8

Wachter, 2001, Rectal sequelae after conformal radiotherapy of prostate cancer: dose–volume histograms as predictive factors, Radiother Oncol, 59, 65, 10.1016/S0167-8140(01)00281-X

Aubin, 2003, Robustness and precision of an automatic marker detection algorithm for online prostate daily targeting using a standard V-EPID, Med Phys, 30, 1825, 10.1118/1.1584041

Trotti, 2003, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Semin Radiat Oncol, 13, 176, 10.1016/S1053-4296(03)00031-6

Cox, 1995, Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC), Int J Radiat Oncol Biol Phys, 31, 1341, 10.1016/0360-3016(95)00060-C

Wei, 2000, Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer, Urology, 56, 899, 10.1016/S0090-4295(00)00858-X

Collett, 1991

Leemis, 1996, A comparison of approximate interval estimators for the Bernoulli parameter, Am Stat, 50, 63, 10.2307/2685046

Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9

Collins, 1991, Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique, Clin Oncol (R Coll Radiol), 3, 127, 10.1016/S0936-6555(05)80831-3

Livsey, 2003, Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis, Int J Radiat Oncol Biol Phys, 57, 1254, 10.1016/S0360-3016(03)00752-1

Soete, 2006, Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity, Radiother Oncol, 80, 78, 10.1016/j.radonc.2006.06.005

Martin, 2007, Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma, Int J Radiat Oncol Biol Phys, 69, 1084, 10.1016/j.ijrobp.2007.04.049

Williams, 2006, An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk, Int J Radiat Oncol Biol Phys, 65, 351, 10.1016/j.ijrobp.2005.12.007

Lukka, 2005, Randomized trial comparing two fractionation schedules for patients with localized prostate cancer, J Clin Oncol, 23, 6132, 10.1200/JCO.2005.06.153

Khoo, 2008, Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial, Clin Oncol (R Coll Radiol), 20, 12, 10.1016/j.clon.2007.10.008

Widmark, 2005, Dose escalation radiotherapy of prostate cancer, Radiother Oncol, 76, S83, 10.1016/S0167-8140(05)81141-7

McNair, 2008, A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy, Int J Radiat Oncol Biol Phys, 71, 41, 10.1016/j.ijrobp.2007.09.002